Publication
Title
EGFR-directed therapies in squamous cell carcinoma of the head and neck
Author
Abstract
The EGF receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). EGFR-directed therapies include monoclonal antibodies and tyrosine kinase inhibitors. The addition of the monoclonal antibody cetuximab to irradiation improves the outcome in locoregionally advanced SCCHN. The addition of an EGFR-directed monoclonal antibody, particularly cetuximab, to a platinum-based chemotherapy improves the outcome in recurrent/metastatic SCCHN. EGFR-directed monoclonal antibodies have activity in platinum-refractory SCCHN, although the benefit might be less than expected. The activity of EGFR-directed tyrosine kinase inhibitors in SCCHN so far has been disappointing.
Language
English
Source (book)
EGFR inhibitors in cancer treatment / Ciardiello, Fortunato [edit.]
Publication
London : Future Medicine, 2012
ISBN
978-1-78084-026-0
Volume/pages
p. 60-71
Full text (Publisher's DOI)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identification
Creation 13.03.2014
Last edited 22.11.2016
To cite this reference